SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov. 4, 2004--Conceptus, Inc. (NASDAQ:CPTS) announced today that the Centers for Medicare and Medicaid Services (CMS) has released the Final Rule for the 2005 ...
Essure's manufacturer says clinical trials show the procedure is 99.83 percent effective at preventing pregnancy over a five-year period when used according to approved instructions. But that rate is ...
MOUNTAIN VIEW, Calif., Sept. 13, 2010 (GLOBE NEWSWIRE) -- Conceptus Inc. (Nasdaq:CPTS), developer of the Essure (R) procedure, the most effective non-surgical permanent birth control method available, ...
After months of consideration, FDA has revealed next steps in its oversight of Essure permanent birth control. The agency is requiring maker Bayer to add a boxed warning and patient decision checklist ...
Co announces the approval of its third generation Essure permanent birth control system by the FDA. System modifications include changes to the delivery system that reduce the number of steps a ...
Called Essure, the implant is sold as a nonsurgical and permanent birth control procedure. The U.S. Food and Drug Administration has received more than 5,000 reports regarding the device, mostly from ...
MOUNTAIN VIEW, Calif., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, ...
WHIPPANY, N.J., July 26, 2018 /PRNewswire/ -- Bayer is reminding women with Essure that the safety profile of Essure, the only Food and Drug Administration (FDA)-approved non-incisional form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback